Journal Mobile Options
Table of Contents
Vol. 87, No. 4, 2008
Issue release date: May 2008
Section title: Clinical Neuroendocrinology and Neuroendocrine Tumours
Neuroendocrinology 2008;87:223–232
(DOI:10.1159/000113128)

Quantitative Gene Expression of Somatostatin Receptors and Noradrenaline Transporter Underlying Scintigraphic Results in Patients with Neuroendocrine Tumors

Binderup T.a, b · Knigge U.a, c · Mellon Mogensen A.d · Palnaes Hansen C.c · Kjaer A.a, b
aCluster for Molecular Imaging, Faculty of Health Science, University of Copenhagen, and bDepartment of Clinical Physiology, Nuclear Medicine and PET and cDepartment of Abdominal Surgery C, and dDepartment of Pathology, Rigshospitalet Hospital, Copenhagen, Denmark

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Neuroendocrinology and Neuroendocrine Tumours

Received: 7/30/2007
Accepted: 11/20/2007
Published online: 1/14/2008
Issue release date: May 2008

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 2

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN

Abstract

Aim: To measure, by a quantitative approach, the gene expression underlying the results of somatostatin receptor (sst) scintigraphy (111In-DTPA-octreotide) and noradrenaline transporter (NAT) scintigraphy (123I-MIBG) in patients with neuroendocrine (NE) tumors. Methods: The gene expression of somatostatin receptors 1–5 (sst) and NAT was measured quantitatively by real-time PCR in a group of patients with NE tumors (n = 14) and compared to a group of patients with colorectal adenocarcinomas (n = 15). If available, scintigraphic results were compared with gene expression results (9 octreotide and 3 MIBG scintigraphies). Results: The sst2 was upregulated in 13 of 14 patients (93%) with NE tumors, and the absolute level of gene expression was highest for sst2. Gene expression alterations of NAT and the other sst subtypes were more variable. Gene expression of sst2 was in all cases in agreement with positive octreotide scintigraphies. In 2 of 3 cases where MIBG scintigraphy was positive, NAT was also upregulated. Sst2 was generally downregulated in the colorectal tumor group with the gene expression of the other receptors being more heterogeneous. Conclusions: In general, changes in gene expression of sst2 corresponded with scintigraphic results. Our data support that sst2 is the best target for visualization of NE tumors, whereas NAT is only a useful target in a subpopulation of NE tumors. Comparison of scintigraphic results with quantitative gene expression may be used to achieve a better understanding of the link between them, which in turn could aid in planning and development of noninvasive molecular imaging of key molecular processes.

© 2008 S. Karger AG, Basel


  

Author Contacts

Tina Binderup
Cluster for Molecular Imaging, BMI 12.3.11
Blegdamsvej 3
DK–2200 Copenhagen N (Denmark)
Tel. +45 35 32 75 33, Fax +45 35 32 75 46, E-Mail tinab@mfi.ku.dk

  

Article Information

Received: July 30, 2007
Accepted after revision: November 20, 2007
Published online: January 14, 2008
Number of Print Pages : 10
Number of Figures : 4, Number of Tables : 2, Number of References : 35

  

Publication Details

Neuroendocrinology (International Journal for Basic and Clinical Studies on Neuroendocrine Relationships)

Vol. 87, No. 4, Year 2008 (Cover Date: May 2008)

Journal Editor: Millar R.P. (Edinburgh)
ISSN: 0028–3835 (Print), eISSN: 1423–0194 (Online)

For additional information: http://www.karger.com/NEN


Article / Publication Details

First-Page Preview
Abstract of Clinical Neuroendocrinology and Neuroendocrine Tumours

Received: 7/30/2007
Accepted: 11/20/2007
Published online: 1/14/2008
Issue release date: May 2008

Number of Print Pages: 10
Number of Figures: 4
Number of Tables: 2

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.